Avalo Therapeutics Inc(AVTX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 7:30 PM ET (Korea 9/12 08:30)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.74 | Insider Own | 10.39% | Shs Outstand | 52.9M | Perf Week | -15.16% |
| Market Cap | 0.86B | Forward P/E | - | EPS next Y | -3.97% | Insider Trans | -6.91% | Shs Float | 48.1M | Perf Month | -17.54% |
| Enterprise Value | 0.47B | PEG | - | EPS next Q | -0.59 | Inst Own | 124.87% | Short Float | 25.77% | Perf Quarter | 17.92% |
| Income | -0.10B | P/S | 14408.54 | EPS this Y | 50.96% | Inst Trans | 117.69% | Short Ratio | 10.26 | Perf Half Y | -3.53% |
| Sales | 0.00B | P/B | 1.9 | EPS next 5Y | 18.74% | ROA | -32.5% | Short Interest | 12.39M | Perf YTD | -11.23% |
| Book/sh | 8.48 | P/C | 2.16 | EPS past 3/5Y | 82.35% 70.2% | ROE | -36.27% | 52W High | -33.58% ($24.27) | Perf Year | 48.16% |
| Cash/sh | 7.46 | P/FCF | - | Sales past 3/5Y | -85.16% -61.19% | ROIC | -22.26% | 52W Low | 68.97% ($9.54) | Perf 3Y | -20.89% |
| Dividend Est. | $0.01 (0.07%) | EV/EBITDA | - | EPS Y/Y TTM | 14.74% | Gross Margin | -84.75% | Volatility(W/M) | 6.35% 4.73% | Perf 5Y | -99.79% |
| Dividend TTM | - | EV/Sales | 7773.87 | Sales Y/Y TTM | -86.62% | Oper. Margin | -154844.07% | ATR (14) | 1.13 | Perf 10Y | -99.85% |
| Dividend Ex-Date | - | Quick Ratio | 19.31 | EPS Q/Q | 56.51% | Profit Margin | -170055.93% | RSI (14) | 32.42 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 19.31 | Sales Q/Q | - | SMA20 | -16.46% ($19.3) | Beta | 0.69 | Target Price | $44.91 |
| Payout | - | Debt/Eq | 0 | Earnings | 2026/8/6 | SMA50 | -15.44% ($19.06) | Rel Volume | 2.09 | Prev Close | $17.18 |
| Employees | 33 | LT Debt/Eq | 0 | EPS/Sales Surpr. | -42.44% - | SMA200 | -4.72% ($16.92) | Avg Volume(3M) | 1.21M | Price | $16.12 |
| IPO | 2015/11/13 | Option/Short | Yes/Yes | Trades | 12862 | Volume | 2,523,944 | Change | -6.17% |
Company
AVTX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Avalo Therapeutics, ticker AVTX, is a clinical-stage biotech company developing novel antibody therapeutics that target immune-mediated inflammatory diseases. Centered on its lead asset abdakibart (development code AVTX-009), a monoclonal antibody targeting interleukin-1 beta, the company is building a pipeline aimed at chronic inflammatory indications such as hidradenitis suppurativa. With no product revenue of its own, it represents a typical clinical-stage biotech structure in which corporate value is driven by clinical progress and capital raises.
Over the past 1 year, roughly in the middle
34% below its 1-year high.
AVTX has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +51.0% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -20.9% if bought 5 years ago.
Tap to view numbers
The dividend is on the small side
Pays 0.07% annually in dividends.
Tap to view numbers
Short interest is a burden
Institutions hold 124.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
MEDI 0.01%
XBI 0.00%
TMED 0.00%
IWC 0.00%
TNXT 0.00%It ranks #4 in the industry
Based on market cap of $865M.
AVTX $865M PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is AVTX?
AVTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of AVTX?
The market cap of AVTX is approximately $865M, ranking 2,769 within its sector.
Does AVTX pay dividends?
AVTX has a dividend yield of approximately 0.07%, with an annual dividend of $0.01.
What is the 52-week high and low for AVTX?
AVTX has recorded a 52-week high of $24.27 and a low of $9.54.
